Hologic Exhibits at Arab Summit - Analyst Blog
January 29 2013 - 1:39PM
Zacks
Hologic Inc. (HOLX), a leading provider of
healthcare products for women, is currently showcasing some of its
latest offerings at the 38th Arab Health Congress at the Dubai
International Convention and Exhibition Centre. The company
undertook this marketing initiative mainly to attract potential
customers from the Middle-East. The conference is likely to host
83,000 medical experts from 142 countries.
Some of the Hologic’s products displayed at the conference
include market leading 2D and 3D mammography systems (Selenia
Dimensions) for breast tomosynthesis, the SecurView diagnostic
workstation, and the Atec breast biopsy system. Also featured are
the Panther system and the associated Aptima assay, which were
inducted into Hologic’s portfolio with the acquisition of Gen-Probe
in August 2012.
The ThinPrep Pap Test and ThinPrep Imaging systems for cervical
cancer screening featured at the event are the driving factor
behind growth in the company’s Diagnostics business. These apart,
Hologic's Discovery bone densitometry platform, NovaSure
endometrial ablation system and MyoSure tissue removal device are
also on display.
In an effort to expand its global reach, Hologic is building on
its international infrastructure and fortifying management
resources, particularly in the emerging markets of China, Latin
America, the Middle East and Eastern Europe. In fiscal 2012, the
company generated 27% of its revenues from international
operations.
As a part of its growth strategy to focus on international
markets and the Middle East, the company is opening a new office in
Dubai Healthcare City. The office is scheduled to open in the first
quarter of 2013.
However, over the past few quarters, Hologic witnessed several
challenges in the form of economic uncertainties in Europe, slower
sales cycles and increasing pricing pressure. Moreover, fluctuating
foreign currency might adversely affect its international revenues
and operating results, particularly in the Diagnostics segment,
which has maximum exposure to international markets.
The stock carries a Zacks Rank #3, which translates into a
short-term Hold rating. Medical instrument companies, such as
Cantel Medical Corp. (CMN), Delcath
Systems, Inc. (DCTH) and Cyberonics Inc.
(CYBX) with Zacks Rank #1 (Strong Buy), are expected to do
well.
CANTEL MED CORP (CMN): Free Stock Analysis Report
CYBERONICS INC (CYBX): Free Stock Analysis Report
DELCATH SYS INC (DCTH): Free Stock Analysis Report
HOLOGIC INC (HOLX): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cantel Medical (NYSE:CMD)
Historical Stock Chart
From Jul 2023 to Jul 2024